ArticleBMC nephrology2026
Association of the ratio of non-HDL-cholesterol to HDL-cholesterol with clinical and pathological characteristics in diabetic kidney disease.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionDiabetic kidney disease (DKD) is a severe complication of diabetes (DM), and dyslipidemia has a vital role in its progression. It is necessary to identify lipid-related biomarkers related to disease severity and prognosis in DKD to facilitate early risk stratification and prevent progression to advanced renal disease. The non-high-density lipoprotein cholesterol (non-HDL-C) to HDL-C ratio (NHHR), an emerging composite lipid metric, has demonstrated potential in assessing metabolic and cardiovascular risks. This investigation was designed to examine the link between NHHR and clinicopathological characteristics, as well as renal outcomes in individuals with DKD and T2DM.
methodsA total of 521 individuals with DKD and T2DM were retrospectively enrolled. Demographic, laboratory, and renal outcomes data were collected. Renal histopathology was assessed in 208 individuals with biopsy-proven DKD. Linear, ordinal logistic and Cox regression analyses were utilized to assess the link between NHHR and clinicopathological parameters and the risk of end-stage kidney disease (ESKD), respectively. Nested models were utilized to compare the prognostic value of NHHR against conventional lipid parameters.
resultsHigher NHHR levels were significantly associated with poorer glycemic control, advanced glomerular lesions, and a higher risk of progressing to ESKD. Multivariable Cox regression analysis considered NHHR as an independent indicator of progressing to ESKD after the adjustment for conventional risk factors. Furthermore, the nested model analysis demonstrated better prognostic value of NHHR compared with conventional lipid parameters. Subgroup analysis illustrated that high NHHR was significantly related to high ESKD risk across subgroups, such as varied ages, sexes, BMI classifications, and in patients with established renal dysfunction or albuminuria.
conclusionNHHR could act as a potential biomarker for risk stratification in DKD and predicting renal outcomes, meriting prospective validation for clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.